Towards disease-oriented dosing of rapamycin for longevity: does aging exist or only age-related diseases?

Area of Science:

• Gerontology
• Pharmacology
• Biogerontology

Background:

• Aging is associated with a high incidence of life-limiting, age-related diseases.
• The progression of age-related diseases varies significantly among individuals.
• Current understanding of aging lacks a unified theory explaining disease onset.

Purpose of the Study:

• To explore the potential of rapamycin as a prophylactic agent against age-related diseases.
• To investigate if rapamycin can delay the onset and progression of specific life-limiting diseases.
• To present the hyperfunction theory of quasi-programmed diseases as an alternative to the traditional concept of aging.

Main Methods:

• Review of existing literature on rapamycin and age-related diseases.
• Analysis of rapamycin's mechanism in decelerating disease development.
• Conceptual framework of the hyperfunction theory.

Main Results:

• Rapamycin, when administered at disease-oriented dosages over time, may delay the onset of age-related diseases.
• Individuals taking rapamycin might experience a longer lifespan compared to those not taking it.
• The hyperfunction theory provides an alternative perspective on age-related diseases.

Conclusions:

• Rapamycin shows promise as a prophylactic intervention to extend healthspan by delaying age-related diseases.
• Targeting disease onset with drugs like rapamycin may be a viable strategy for increasing longevity.
• The hyperfunction theory offers a new paradigm for understanding and potentially treating age-related conditions.